1. Home
  2. CGTX
  3. CGTX News

Latest Cognition Therapeutics Inc. (CGTX) News on July 13, 2025

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)
CGTX

GlobeNewswire

18 days ago

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)

Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
CGTX

GlobeNewswire

a month ago

Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies
CGTX

GlobeNewswire

a month ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

Cognition announces outcomes from trial of zervimesine for geographic atrophy
CGTX

Clinical Trials Arena

2 months ago

Cognition announces outcomes from trial of zervimesine for geographic atrophy

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
CGTX

GlobeNewswire

2 months ago

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy
CGTX

GlobeNewswire

2 months ago

Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
CGTX

GlobeNewswire

2 months ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes
CGTX

GlobeNewswire

3 months ago

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025
CGTX

GlobeNewswire

4 months ago

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025

CGTX

GuruFocus.com

4 months ago

Cognition Therapeutics Inc (CGTX) Q4 2024 Earnings Call Highlights: Strategic Focus on ...

CGTX

Thomson Reuters StreetEvents

4 months ago

Q4 2024 Cognition Therapeutics Inc Earnings Call

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
CGTX

GlobeNewswire

4 months ago

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
CGTX

GlobeNewswire

4 months ago

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results
CGTX

GlobeNewswire

4 months ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing
CGTX

GlobeNewswire

4 months ago

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

Life Sciences Investor Forum Agenda Announced for March 13th
CGTX

GlobeNewswire

4 months ago

Life Sciences Investor Forum Agenda Announced for March 13th

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference
CGTX

GlobeNewswire

4 months ago

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD
CGTX

GlobeNewswire

5 months ago

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy
CGTX

GlobeNewswire

5 months ago

Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy

Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit
CGTX

GlobeNewswire

5 months ago

Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)
CGTX

GlobeNewswire

5 months ago

Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)

CGTX

MT Newswires

5 months ago

B. Riley Adjusts Cognition Therapeutics Price Target to $2 From $1.50, Maintains Buy Rating

Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC
CGTX

GlobeNewswire

5 months ago

Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences
CGTX

GlobeNewswire

6 months ago

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data
CGTX

TipRanks

7 months ago

B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data

CGTX

MT Newswires

7 months ago

B. Riley Upgrades Cognition Therapeutics to Buy From Neutral, Lifts PT to $1.50 From $1

Cognition Therapeutics announces results in Phase 2 study of CT1812
CGTX

TipRanks

7 months ago

Cognition Therapeutics announces results in Phase 2 study of CT1812

CGTX

MT Newswires

7 months ago

Cognition Therapeutics Says Study of Drug to Treat Lewy Body Dementia Meets Primary Endpoint; Shares Jump

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
CGTX

GlobeNewswire

7 months ago

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
CGTX

Simply Wall St.

7 months ago

We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CGTX

Zacks

7 months ago

Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis
CGTX

TipRanks

8 months ago

Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies
CGTX

GlobeNewswire

8 months ago

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population
CGTX

GlobeNewswire

8 months ago

Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population

Life Sciences Investor Forum: Presentations Now Available for Online Viewing
CGTX

GlobeNewswire

8 months ago

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
CGTX

GlobeNewswire

8 months ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Life Sciences Investor Forum Agenda Announced for November 14th
CGTX

GlobeNewswire

8 months ago

Life Sciences Investor Forum Agenda Announced for November 14th

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum
CGTX

GlobeNewswire

8 months ago

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
CGTX

GlobeNewswire

8 months ago

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
CGTX

GlobeNewswire

8 months ago

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
CGTX

GlobeNewswire

9 months ago

Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
CGTX

GlobeNewswire

9 months ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

CGTX

GuruFocus.com

9 months ago

Cognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ...

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
CGTX

GlobeNewswire

9 months ago

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
CGTX

GlobeNewswire

9 months ago

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
CGTX

GlobeNewswire

10 months ago

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

CGTX

MT Newswires

a year ago

Cognition Therapeutics Reports Positive Results for Alzheimer's Drug in Study

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

Cognition Therapeutics to Report Second Quarter 2024 Financial Results
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

CGTX

MT Newswires

a year ago

Cantor Fitzgerald Downgrades Cognition Therapeutics to Neutral From Overweight

Cognition Therapeutics’ stock dips 43% following trial results for Alzheimer’s candidate
CGTX

Clinical Trials Arena

a year ago

Cognition Therapeutics’ stock dips 43% following trial results for Alzheimer’s candidate

Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024

Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
CGTX

GlobeNewswire

a year ago

Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
CGTX

Simply Wall St.

a year ago

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

FDA panel votes to recommend Eli Lilly's Alzheimer's drug
CGTX

Yahoo Finance Video

a year ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

CGTX

GlobeNewswire

a year ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit
CGTX

Reuters

a year ago

California seeks company profits in Big Oil climate lawsuit

CGTX

USA TODAY

a year ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
CGTX

Business Wire

a year ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
CGTX

GlobeNewswire

a year ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas
CGTX

Business Wire

a year ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research
CGTX

GlobeNewswire

a year ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

CGTX

MT Newswires

a year ago

Chardan Research Initiates Cognition Therapeutics With Buy Rating, $11 Price Target

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call Transcript
CGTX

Insider Monkey

a year ago

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call Transcript

CGTX

Thomson Reuters StreetEvents

a year ago

Q4 2023 Cognition Therapeutics Inc Earnings Call

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock

Cognition Therapeutics Announces Proposed Public Offering of Common Stock
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics Announces Proposed Public Offering of Common Stock

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies

Cognition Therapeutics to Present at the TD Cowen Health Care Conference
CGTX

GlobeNewswire

a year ago

Cognition Therapeutics to Present at the TD Cowen Health Care Conference

New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
CGTX

GlobeNewswire

a year ago

New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812

Trinseo (NYSE:TSE) shareholders have endured a 87% loss from investing in the stock three years ago
CGTX

Simply Wall St.

a year ago

Trinseo (NYSE:TSE) shareholders have endured a 87% loss from investing in the stock three years ago

CGTX

Business Wire

a year ago

Mytheresa Announces Second Quarter of Fiscal Year 2024 Earnings Release and Conference Call; Participating in Upcoming Investor Conferences

Murphy Oil (MUR) Lags Q4 Earnings Estimates
CGTX

Zacks

a year ago

Murphy Oil (MUR) Lags Q4 Earnings Estimates

Xiao-I (NASDAQ: AIXI) and ABB (SIX: ABBN) Forge Strategic Partnership to Drive Industrial Digital Intelligence Advancement with Hua Zang Universal Large Language Model
CGTX

PR Newswire

a year ago

Xiao-I (NASDAQ: AIXI) and ABB (SIX: ABBN) Forge Strategic Partnership to Drive Industrial Digital Intelligence Advancement with Hua Zang Universal Large Language Model

Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback
CGTX

Zacks

a year ago

Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback

CGTX

Zacks Small Cap Research

a year ago

AIXI: Initiating Coverage – The AI hype cycle subsides but opportunities and challenges lie ahead in 2024

Wayfair (W) Soars 10.3%: Is Further Upside Left in the Stock?
CGTX

Zacks

a year ago

Wayfair (W) Soars 10.3%: Is Further Upside Left in the Stock?

Hear from Mark D. Walker, CEO of Direct Digital Holdings, Inc. Live at ICR Conference 2024
CGTX

IPO-Edge.com

a year ago

Hear from Mark D. Walker, CEO of Direct Digital Holdings, Inc. Live at ICR Conference 2024

Has Leidos (LDOS) Outpaced Other Aerospace Stocks This Year?
CGTX

Zacks

a year ago

Has Leidos (LDOS) Outpaced Other Aerospace Stocks This Year?

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
CGTX

Simply Wall St.

a year ago

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Vox Announces New Revolving Credit Facility of up to $25 Million with Bank of Montreal
CGTX

ACCESSWIRE

a year ago

Vox Announces New Revolving Credit Facility of up to $25 Million with Bank of Montreal

China Automotive Systems (NASDAQ:CAAS) Is Doing The Right Things To Multiply Its Share Price
CGTX

Simply Wall St.

a year ago

China Automotive Systems (NASDAQ:CAAS) Is Doing The Right Things To Multiply Its Share Price

CGTX

Investing.com

a year ago

4 big dividends this week: Lennar hikes dividend, announces $5B buyback

Office Properties' Dividend Gets Whacked: Isolated Case Or The Start of A Trend?
CGTX

Benzinga

2 years ago

Office Properties' Dividend Gets Whacked: Isolated Case Or The Start of A Trend?

CGTX

Thomson Reuters StreetEvents

2 years ago

Q2 2024 Richardson Electronics Ltd Earnings Call

MISTRAS Group to Participate in Sidoti Micro-Cap Virtual Investor Conference on January 17-18, 2024
CGTX

GlobeNewswire

2 years ago

MISTRAS Group to Participate in Sidoti Micro-Cap Virtual Investor Conference on January 17-18, 2024

VOXX International Corporation (NASDAQ:VOXX) Q3 2024 Earnings Call Transcript
CGTX

Insider Monkey

2 years ago

VOXX International Corporation (NASDAQ:VOXX) Q3 2024 Earnings Call Transcript

CGTX

GuruFocus.com

2 years ago

Richardson Electronics Ltd Reports Q2 Fiscal 2024 Results Amid Economic Challenges

City Office REIT Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call
CGTX

PR Newswire

2 years ago

City Office REIT Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

Share on Social Networks: